As of 2026-10-26, DNTH scores 20out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. DNTH trades at $79.33, within its fair-value band.
DNTH scores 20 out of 100 on QNTM's five-factor model — a low-conviction reading — at 20 the factor profile is among the weaker names in the universe. Its strongest factor is quality at 33 (soft), where earnings quality and balance-sheet strength stand out, followed by volume at 28. The weakest is value at 0, where valuation looks stretched. Among Healthcare stocks it sits in the lower 3% of Healthcare names by composite.
On valuation, DNTH is priced near the floor of its own recent range — the cheap end on the model's valuation read. The blended composite before the macro overlay was 20. Same-sector names the model rates nearby include HALO, VEEV, THC.
This is a descriptive factor read on DNTH, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where DNTH sits on the model's measures today, and can change as new data arrives.
QNTM’s descriptive fair-value band for DNTH runs $69.90–$118.80. Current price $79.33 sits within its fair-value band. This is valuation context, not a price target.
QNTM rescores DNTH and ~1,400 other names every session. Track it, get notified the moment it crosses a conviction tier, and see the full signal history.
Start free →QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.